



NDA 018081/ S-049
NDA 018082/ S-034
NDA 018723/ S-041
NDA 019680/ S-028
NDA 020593/ S-019
NDA 021168/ S-019

SUPPLEMENT APPROVALS

AbbVie Inc.
Attention: Richard Leber
Senior Manager, Regulatory Affairs
1 N. Waukegan Road
Dept. PA77/Bldg. AP30
North Chicago, IL 60064

Dear Mr. Leber:

Please refer to your Supplemental New Drug Applications (sNDAs) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

Application	Drug Product	Submitted on:	Received on:
NDA 018081/S-049	Depakene (valproic acid) Capsules	December 20, 2013	December 20, 2013
NDA 018082/S-034	Depakene (valproic acid) Oral Solution		
NDA 018723/S-041	Depakote (divalproex sodium) Delayed Release Tablets		
NDA 019680/S-028	Depakote Sprinkle Capsules (divalproex sodium coated particles in capsules)		
NDA 020593/S-019	Depacon (valproate sodium) Injection		
NDA 021168/S-019	Depakote ER (divalproex sodium) Extended Release Tablets		

We acknowledge receipt of your amendment dated May 30, 2014.

The December 20, 2013, submissions constituted a complete response to our August 17, 2012, action letter.

These “Changes Being Effected” supplemental new drug applications proposed a response to the Agency’s August 17, 2012, Complete Response Letter and subsequent related communications, and provide for the addition of “Fractures, decreased bone mineral density, osteopenia, osteoporosis” to the *Adverse Reactions* section of prescribing information.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

NDA 018081/ S-049
NDA 018082/ S-034
NDA 018723/ S-041
NDA 019680/ S-028
NDA 020593/ S-019
NDA 021168/ S-019
Page 3

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Stacy Metz, PharmD, Regulatory Project Manager, at (301) 796-2139.

Sincerely,

{See appended electronic signature page}

Alice Hughes, M.D.
Deputy Director for Safety
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ALICE HUGHES
06/19/2014